In PDX mouse models using primary human JAK2-V617F-expressing bone marrow of MPN patients, the combination of ruxolitinib and the MEK inhibitor trametinib significantly inhibited the growth of transplanted cells and induced molecular remission compared to mice treated with ruxolitinib alone. This evidence concerns the gene MAP2K7 and myeloproliferative disorder.